Download Image
    
Share
  
Post
Vidofludimus Calcium for COVID-19
1 study with 220 patients
Hospital Icon Control Serious Outcome Risk
Hospital Icon Vidofludimus
No significant improvements are seen in meta analysis to date.
COVID-19 Vidofludimus Calcium studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies 0% Mortality 0% RCTs 0% Late 0% Favorsvidofludimus calcium Favorscontrol
Oct 15
2022
 Vehreschild et al., Infectious Diseases and Therapy, doi:10.1007/s40121-022-00690-0 Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
no change in mortality (p=1), no change in ventilation (p=1), and no change in progression (p=1). RCT 223 hospitalized COVID-19 patients showing no significant difference in mortality, ventilation, or progression with vidofludimus calcium (a DHODH inhibitor) versus placebo.